B cells in multiple sclerosis

References

• Esiri, M. M. 1980. Multiple sclerosis: a quantitative and qualitative study of immunoglobulin-containing cells in the central nervous system. Neuropathol. Appl. Neurobiol. 6: 9–21
   PubMed Web of Science ®Google Scholar
• Serafini, B., B. Rosicarelli, R. Magliozzi, et al. 2004. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 14: 164–144
   PubMed Web of Science ®Google Scholar
• Lucchinetti, C. F., B. F. G. Popescu, R. F. Bunyan, et al. 2011. Inflammatory cortical demyelination in early multiple sclerosis. N. Engl. J. Med. 365: 2188–2197
   PubMed Web of Science ®Google Scholar
• Obermeier, B., R. Mentele, J. Malotka, et al. 2008. Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis. Nat. Med. 14: 688–693
   PubMed Web of Science ®Google Scholar
• Brändle, S., B. Obermeier, M. Senel, et al. 2016. Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins. Proc. Natl. Acad. Sci. USA. 113: 7864–7869
   PubMed Web of Science ®Google Scholar
• Brennan, K. M., F. Galban-Horcajo, S. Rinaldi, et al. 2011. Lipid arrays identify myelin-derived lipids and lipid complexes as prominent targets for oligoclonal band antibodies in multiple sclerosis. J. Neuroimmunol. 238: 87–95
   PubMed Web of Science ®Google Scholar
• Walsh, M. J., and W. W. Tourtellotte. 1986. Temporal invariance and clonal uniformity of brain and cerebrospinal IgG, IgA, and IgM in multiple sclerosis. J. Exp. Med. 163: 41–53
   PubMed Web of Science ®Google Scholar
• Neumann, H., and H. Wekerle. 1998. Neuronal control of the immune response in the central nervous system: linking brain immunity to neurodegeneration. J. Neuropathol. Exp. Neurol. 57: 1–9
   PubMed Web of Science ®Google Scholar
• Krumbholz, M., D. Theil, T. Derfuss, et al. 2005. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J. Exp. Med. 201: 195–200
   PubMed Web of Science ®Google Scholar
• von Büdingen, H. C., T. C. Kuo, M. Sirota, et al. 2012. B cell exchange across the blood-brain barrier in multiple sclerosis. J. Clin. Invest. 122: 4533–4543
   PubMed Web of Science ®Google Scholar
• Lucchinetti, C. F., W. Brück, J. Parisi, et al. 2000. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47: 707–717
   PubMed Web of Science ®Google Scholar
• Keegan, M., F. König, R. McClelland, et al. 2005. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet. 366: 579–582
   PubMed Web of Science ®Google Scholar
• Magliozzi, R., O. Howell, A. Vora, et al. 2007. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 130: 1089–1104
   PubMed Web of Science ®Google Scholar
• Hauser, S. L., E. Waubant, D. L. Arnold, et al. 2008. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358: 676–688
   PubMed Web of Science ®Google Scholar
• Srivastava, R., M. Aslam, S. R. Kalluri, et al. 2012. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N. Engl. J. Med. 367: 115–123
   PubMed Web of Science ®Google Scholar
• Pröbstel, A. K., J. Kuhle, A. C. Lecourt, et al. 2016. Multiple sclerosis and antibodies against KIR4.1. N. Engl. J. Med. 374: 1496–1498
   PubMed Web of Science ®Google Scholar
• Derfuss, T., C. Linington, R. Hohlfeld, and E. Meinl. 2010. Axo-glial antigens as targets in multiple sclerosis: implications for axonal and grey matter injury. J. Mol. Med. 88: 753–761
   PubMed Web of Science ®Google Scholar
• Bar-Or, A., R. Q. Hintzen, R. C. Dale, et al. 2016. Immunopathophysiology of pediatric CNS inflammatory demyelinating diseases. Neurology. 87: S12–S19
   PubMed Web of Science ®Google Scholar
• Probstel, A. K., G. Rudolf, K. Dornmair, et al. 2015. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. J. Neuroinflamm. 12: 46
   Web of Science ®Google Scholar
• Mayer, M. C., C. Breithaupt, M. Reindl, et al. 2013. Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory CNS diseases. J. Immunol. 191: 3594–3604
   PubMed Web of Science ®Google Scholar
• Krumbholz, M., T. Derfuss, R. Hohlfeld, and E. Meinl. 2012. B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat. Rev. Neurol. 8: 613–623
   PubMed Web of Science ®Google Scholar
• Krishnamoorthy, G., H. Lassmann, H. Wekerle, and A. Holz. 2006. Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation. J. Clin. Invest. 116: 2385–2392
   PubMed Web of Science ®Google Scholar
• Krishnamoorthy, G., A. Saxena, L. T. Mars, et al. 2009. Myelin specific T cells also recognize neuronal autoantigen in a transgenic mouse model of multiple sclerosis. Nature Med. 15: 626–632
   PubMed Web of Science ®Google Scholar
• Pöllinger, B., G. Krishnamoorthy, K. Berer, et al. 2009. Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells. J. Exp. Med. 206: 1303–1316
   PubMed Web of Science ®Google Scholar
• Berer, K., M. Mues, M. Koutrolos, et al. 2011. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature. 479: 538–541
   PubMed Web of Science ®Google Scholar
• Wekerle, H. 2015. Nature plus nurture: the triggering of multiple sclerosis. Swiss Med. Wkly. 145: w14189
   PubMed Web of Science ®Google Scholar
• Gilhus, N. E., and J. J. Verschuuren. 2015. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 14: 1023–1036
   PubMed Web of Science ®Google Scholar
• Edwards, J. C. W., and G. Cambridge. 2006. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat. Rev. Immunol. 6: 394–403
   PubMed Web of Science ®Google Scholar
• Salzer, J., R. Svenningsson, P. Alping, et al. 2016. Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy. Neurology. 87: 2074–2081
   PubMed Web of Science ®Google Scholar
• Hauser, S. L. 2015. The Charcot Lecture – beating MS: a story of B cells, with twists and turns. Mult. Scler. 21: 8–21
   PubMed Web of Science ®Google Scholar
• Kappos, L., H. P. Hartung, M. S. Freedman, et al. 2014. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Neurol. 13: 353–363
   PubMed Web of Science ®Google Scholar
• Vincent, F. B., E. F. Morand, P. Schneider, and F. Mackay. 2014. The BAFF/APRIL system in SLE pathogenesis. Nat. Rev. Rheumatol. 10: 365–373
   PubMed Web of Science ®Google Scholar